Retrospective Study
Copyright ©The Author(s) 2025.
World J Gastrointest Surg. Mar 27, 2025; 17(3): 101061
Published online Mar 27, 2025. doi: 10.4240/wjgs.v17.i3.101061
Table 1 Comparison of clinical data between sphincter-preserved and sphincter-unpreserved groups, n (%)
Factors
Sphincter-preserved group (n = 150)
Sphincter-unpreserved group (n = 29)
Statistics
P value
Age (years)67 (59, 72)65 (57, 73)0.7190.472
Sex0.0010.985
    Male98 (65.3)19 (65.5)
    Female52 (34.7)10 (34.5)
Residence3.9510.047
    Rural63 (42.0)18 (62.1)
    Urban87 (58.0)11 (37.9)
BMI (kg/m2)22.8 ± 3.222.5 ± 3.30.5870.558
Time since onset of first symptoms or diagnosis (months)2 (1, 6)3 (2, 7)1.2250.220
Duration of preoperative care (days)7 (5, 9)7 (6, 10)0.9250.355
Preoperative bowel preparation time (days)6 (4, 7)6 (5, 7)0.7310.465
Colonic polyps72 (48.0)8 (27.6)4.0970.043
Rectal polyps20 (13.3)1 (3.4)1.4380.230
Tumours with bleeding107 (71.3)20 (69.0)0.0660.797
Tumours causing obstruction22 (14.7)1 (3.4)1.8210.177
Neoadjuvant chemotherapy20 (13.3)10 (34.5)6.3490.012
Preoperative radiotherapy16 (10.7)7 (24.1)2.8270.093
History of hypertension53 (35.3)12 (41.4)0.3840.535
Diabetes mellitus22 (14.7)7 (24.1)0.9840.321
Coronary artery disease24 (16.0)2 (6.9)0.9720.324
Peripheral vascular lesions of the lower extremities11 (7.3)5 (17.2)1.8400.175
History of previous abdominal surgery41 (27.3)6 (20.7)0.5540.457
History of recent aspirin use22 (14.7)3 (10.3)0.1040.747
Smoking history26 (17.3)6 (20.7)0.1860.666
Alcohol consumption history20 (13.3)3 (10.3)0.0190.891
Preoperative hypoproteinemia17 (11.3)5 (17.2)0.3340.563
Preoperative anemia13 (8.7)5 (17.2)1.1410.285
Pelvic effusion48 (32.0)8 (27.6)0.2200.639
Clinical stage1.3830.240
    0/I/II95 (63.3)15 (51.7)
    III/IV55 (36.7)14 (48.3)
Tumour T stage0.0300.863
    Tis/T1/T249 (32.7)9 (31.0)
    T3/T4101 (67.3)20 (69.0)
N stage0.3900.532
    N-87 (58.0)15 (51.7)
    N+63 (42.0)14 (48.3)
Degree of tumour differentiation4.0030.144
    Medium differentiation124 (82.7)22 (75.9)
    High differentiation17 (11.3)2 (6.9)
    Low differentiation9 (6.0)5 (17.2)
Mucinous adenocarcinoma14 (9.3)7 (24.1)3.8130.051
Vascular invasion38 (25.3)7 (24.1)0.0180.892
Nerve invasion75 (50.0)22 (75.9)6.5480.011
Preoperative fever of ≥ 37 °C31 (20.7)10 (34.5)2.6270.105
ASA grading0.2830.595
    I/II112 (74.7)23 (79.3)
    III/IV38 (25.3)6 (20.7)
Tumour height69.652< 0.001
    Upper rectum55 (36.7)1 (3.4)
    Middle rectum73 (48.6)2 (6.9)
    Lower rectum22 (14.7)26 (89.7)
Maximum transverse tumour diameter (cm)3.5 (2.8, 4.6)3.8 (3.2, 4.4)0.5020.616
CEA (ng/mL)3.25 (1.60, 10.55)5.79 (3.21, 10.41)2.4440.015
CA19-9 (ng/mL)13.65 (8.02, 21.43)21.61 (12.28, 24.80)2.2990.022
ALB (g/L)38.0 ± 4.138.0 ± 3.80.0010.999
GLU (mmol/L)4.89 (4.35, 5.63)5.24 (4.61, 5.33)0.8490.396
Potassium (mmol/L)3.9 (3.7, 4.2)3.9 (3.8, 4.2)0.5270.598
PT-T (second)12.3 (11.6, 12.9)12.3 (11.7, 12.6)0.0310.975
DD (mg/L)0.77 (0.62, 1.11)0.88 (0.72, 1.72)1.8740.061
WBC (109/L)5.38 (4.54, 6.41)5.75 (5.07, 5.82)1.1060.269
PLT (109/L)203 (166, 239)204 (188, 222)0.6720.502
Table 2 Logistic regression analysis of sphincter preservation in laparoscopic radical rectal cancer surgery
Variable
β
P value
OR
95%CI
Residence1.0460.1312.8450.732-11.063
Colonic polyps-2.2070.0060.1100.023-0.535
Neoadjuvant chemotherapy1.8480.3026.3470.190-211.759
Preoperative radiotherapy0.8070.6742.2410.052-95.916
Mucinous adenocarcinoma2.5040.00912.2301.847-80.999
Nerve invasion1.8360.0126.2721.499-26.247
Tumour height
    Upper rectumRefence
    Middle rectum5.292< 0.001198.82013.665-2892.686
    Lower rectum5.593< 0.001268.63922.203-3250.284
CEA-0.0210.3900.9800.935-1.027
CA19-9-0.0150.2400.9850.961-1.010
DD-0.0130.7550.9870.910-1.071